Elizabeth Dater
Member since: Apr '04
Senior Portfolio Manager at
Forstmann Leff Assoc

Latest Top Picks

Given with what's going on with Vioxx and Cellebrex, this company is very important as the FDA will be asking for lengthier testing on these areas. Looks on this as a fabulous growth story.
A re-structuring story. Very successful management.
A consolidating industry. Benefiting tremendously from technology and geographical expansion.
New entity called spoken audio content which downloads newspaper, textbooks, radio programming. A really good growth story.
Had a big correction so there is a buying opportunity. A story thats growing by about 20% a year. Trading at 15 X earnings.